Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

pre-exposure prophylaxis (PrEP)

This page shows the latest pre-exposure prophylaxis (PrEP) news and features for those working in and with pharma, biotech and healthcare.

GSK’s ViiV submits application for cabotegravir to EMA for HIV-1 prevention

GSK’s ViiV submits application for cabotegravir to EMA for HIV-1 prevention

ViiV Healthcare, which is majority-owned by GSK, has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of cabotegravir long-acting injectable for pre-exposure ... prophylaxis (PrEP) to reduce

Latest news

  • GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention

    The patents in the agreement relate to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP), the first long-acting HIV prevention medicine, to help enable access in least developed, ... The announcement follows the first regulatory

  • MHRA grants approval for AstraZeneca’s Evusheld in the UK MHRA grants approval for AstraZeneca’s Evusheld in the UK

    It is the first antibody combination for pre-exposure prophylaxis (PrEP) against COVID-19 to be licensed in the UK. ... Availability of this antibody medicine now offers an increased likelihood of pre-exposure protection, and all from a single, effective

  • NHS England will make PrEP for HIV available in April NHS England will make PrEP for HIV available in April

    PrEP – or pre-exposure prophylaxis – will be made routinely available to patients considered to be at greater risk of catching HIV, for example if their partner is infected with the virus. ... Now, they will be able to continue on PrEP after the

  • Gilead builds case for Descovy PrEP after FDA approval Gilead builds case for Descovy PrEP after FDA approval

    Reported statistically significant improvements in kidney function. Gilead has reported new head-to-head data between its drugs for HIV pre-exposure prophylaxis (PrEP) to try to encourage uptake of ... PrEP sales, estimated to account for $2bn out of its

  • J&J pledges $500m investment into HIV and tuberculosis R&D J&J pledges $500m investment into HIV and tuberculosis R&D

    Treatments for HIV in particular have seen  increasing advancements in recent years – other key players in this field are Gilead, whose next-generation HIV pre-exposure prophylaxis (PrEP) treatment Descovy (emtricitabine

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest from PMHub

  • World AIDS Day 2018: Fighting the stigma surrounding HIV

    14. Both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) drugs may prevent infection developing. ... PrEP (pre-exposure prophylaxis). Available at: . Accessed November 2018. NHS. Can post-exposure prophylaxis (PEP) stop me getting HIV?

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....

Quick links